Gabapentin
Product Images NDC 53217-282

This is a formula for estimating kidney function in adults using variables such as age, weight, and serum creatinine levels.*

This is a chart showing the mean pain scores for a study conducted over a period of 43 weeks. The study consisted of two dosing periods; the first was a placebo, and the second was Gabapentin at either 1800 or 2400 mg/day. The chart shows the baseline pain score as well as scores for each week of the study.*

This is a graph that shows the proportion of responders (patients with a 50% reduction in pain score) in two controlled PHN studies. The graph contains percentages ranging from 0% to 100% in increments of 10%; the x-axis indicates the percentage, and the y-axis labels each study. The graph shows the response rates for two different dosages of GBP (gabapentin), 2400mg and 3600mg, as well as a placebo (PBO) group. The results indicate that a higher dosage of GBP resulted in a higher percentage of responders. The text also mentions two asterisks, indicating a statistically significant difference between the groups, but it is not clear what they refer to without additional context.*

This text is not-available for generating a useful description as it contains only one word and no context.*

The text consists of only two words: "G" and "glenmark". It is likely that "G" is a letter and "glenmark" is a company name or brand. However, without further context, it is difficult to provide a specific description.*

This appears to be a prescription label for Gabapentin, a medication used to treat seizures and nerve pain. The label indicates that the medication is available in two strengths, 600mg and 400mg, and contains 90 tablets. It also mentions a generic equivalent for the brand-name drug Neurontin. The patient's name and other personal details are not available in this text.*